Trial reportEuropean journal of nuclear medicine and molecular imaging2018
Trial report in European journal of nuclear medicine and molecular imaging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 5 syntheses or guidelines pooled it, 149 citations in OpenAlex.
- Italian Guidelines for the Management of Sporadic Primary Hyperparathyroidism.Endocrine, metabolic & immune disorders drug targets · 2024Guideline
- Assessment and Comparison ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Pooled it
- Pooled it
- Diagnostic performance of choline PET for detection of hyperfunctioning parathyroid glands in hyperparathyroidism: a systematic review and meta-analysis.European journal of nuclear medicine and molecular imaging · 2019Pooled it
- Diagnostic Performance of F-18 Fluorocholine PET/CT for Parathyroid Localization in Hyperparathyroidism: a Systematic Review and Meta-Analysis.Hormones & cancer · 2018Pooled it
- Feasibility of Hyperfunctioning Parathyroid Gland Localization Using [Molecular imaging and biology · 2019Trial
- Additional value of integratedEuropean journal of nuclear medicine and molecular imaging · 2019Trial
- The Diagnostic Accuracy of [Diagnostics (Basel, Switzerland) · 2026Article
- Choline PET/CT in the PSMA Era: Clinical Repositioning, Biological Perspectives, and Emerging Applications.Diagnostics (Basel, Switzerland) · 2026Review
- A Case of Submandibular Ectopic Parathyroid Adenoma: Diagnostic Challenges and Clinical Insights.Balkan medical journal · 2026Article
- Preoperative imaging strategies to optimize surgical treatment in primary hyperparathyroidism (pHPT).BMC surgery · 2026Article
- Injection method alters diagnostic confidence and quantitative metrics in [EJNMMI reports · 2026Article
- Use of bone-SPECT/CT and Na[Frontiers in nuclear medicine · 2025Review
- Conventional imaging techniques plusFrontiers in endocrinology · 2025Article
- PET/CT imaging of bone disorders in dysparathyroidism: a comprehensive review.Frontiers in nuclear medicine · 2025Review
- Bone Mineral Density and First Line Imaging with [Diagnostics (Basel, Switzerland) · 2024Article
- Cost-effectiveness of one-stop-shop [European journal of nuclear medicine and molecular imaging · 2024Article
- Four-dimensional computed tomography as first-line imaging in primary hyperparathyroidism, a retrospective comparison to conventional imaging in a predominantly single adenoma population.EJNMMI reports · 2024Article
- [Management of primary hyperparathyroidism with rare localization of ectopic adenoma parathyroid gland].Problemy endokrinologii · 2024Article
- Head-to-head comparison of [European journal of nuclear medicine and molecular imaging · 2024Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIn this prospective study we compared the accuracy of
methodsBoth
resultsAll patients showed biochemical evidence of primary hyperparathyroidism with a mean serum calcium level of 2.78 ± 0.34 mmol/l and parathormone (PTH) level of 196.5 ± 236.4 pg/ml. The study results in 76 patients with verified histopathology and 3 patients with negative imaging findings were analysed. Three of six patients with negative imaging showed normalized serum PTH and calcium levels on laboratory follow-up at 3 and 6 months, and the results were considered true negative. In a patient-based analysis, the detection rate with
conclusionIn this prospective study,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.